Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [21] Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Lee, Philip
    Kistler, Kristin D.
    Douyon, Luc
    Volodarsky, Raisa
    Young, Alex
    Karve, Sudeep
    Challagulla, Swetha
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (01) : 11 - 22
  • [22] Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Jacobs, Ryan
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 2073 - 2084
  • [23] Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) : 3 - 19
  • [24] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [25] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [26] Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia
    Hou, Jing-Zhou
    Ryan, Kellie
    Du, Senxi
    Fang, Bruno
    Marks, Stanley
    Page, Ray
    Peng, Eileen
    Szymanski, Keith
    Winters, Sharon
    Le, Hannah
    FUTURE ONCOLOGY, 2021, 17 (35) : 4959 - 4969
  • [27] Real-world treatment patterns in first line and relapsed Chronic Lymphocytic Leukemia (CLL)
    Feinberg, Bruce
    Schenkel, Brad
    McBride, Ali
    Ellis, Lorie
    Radtchenko, Janna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S204 - S205
  • [28] Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib
    Jacobs, Ryan
    Wang, Ruibin
    He, Jinghua
    Lu, Xiaoxiao
    Wu, Linda
    Khan, Wasiulla
    Qureshi, Zaina P.
    Levy, Moshe Yair
    BLOOD, 2022, 140 : 8017 - 8018
  • [29] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina P.
    Pinilla-Ibarz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE AMONG US MEDICARE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING FIRST-LINE IBRUTINIB VS CHEMOIMMUNOTHERAPY
    Huang, Q.
    Emond, B.
    Lafeuille, M. H.
    Gupta, D.
    Lefebvre, P.
    Sundaram, M.
    Mato, A.
    VALUE IN HEALTH, 2020, 23 : S44 - S45
12345